Patients whose HIV is resistant to four classes of drugs experience a greater rate of malignancies and higher burden of disease, according to a study published in the journal Open Forum Infectious Diseases. The rate of clinical events or mortality with four-class drug-resistant HIV was 25% over four years.
Disease burden higher with treatment-resistant HIV
Sign up for Specialty Pharmacy SmartBrief
News affecting the specialty pharmacy industry
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.